ViroGates A/S Share Price

Equities

VIRO

DK0061030574

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 08:29:52 26/04/2024 pm IST 5-day change 1st Jan Change
6.5 DKK -11.92% Intraday chart for ViroGates A/S +8.33% +7.97%

Financials

Sales 2022 15.2M 2.18M 182M Sales 2023 6.99M 1M 83.54M Capitalization 38.81M 5.57M 464M
Net income 2022 -9M -1.29M -108M Net income 2023 -12M -1.72M -143M EV / Sales 2022 8.18 x
Net cash position 2022 9.88M 1.42M 118M Net cash position 2023 10.73M 1.54M 128M EV / Sales 2023 4.02 x
P/E ratio 2022
-13.5 x
P/E ratio 2023
-1.72 x
Employees 10
Yield 2022 *
-
Yield 2023
-
Free-Float 72.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day-11.92%
1 week+8.33%
1 month+0.62%
3 months-20.73%
6 months-64.67%
Current year+7.97%
More quotes
1 week
5.66
Extreme 5.66
7.38
1 month
5.32
Extreme 5.32
7.46
Current year
5.32
Extreme 5.32
9.14
1 year
4.98
Extreme 4.98
25.30
3 years
4.98
Extreme 4.98
252.00
5 years
4.98
Extreme 4.98
252.00
10 years
4.98
Extreme 4.98
252.00
More quotes
Managers TitleAgeSince
Founder 61 01/01/01
Chief Executive Officer 56 01/11/01
Director of Finance/CFO 33 01/23/01
Members of the board TitleAgeSince
Director/Board Member 57 01/16/01
Chairman 62 01/22/01
Director/Board Member 63 01/15/01
More insiders
Date Price Change Volume
26/24/26 6.5 -11.92% 424
25/24/25 7.38 +7.27% 150
24/24/24 6.88 +6.17% 103
23/24/23 6.48 +8.91% 5,417
22/24/22 5.95 -0.83% 131,926

Delayed Quote Nasdaq Copenhagen, April 26, 2024 at 08:29 pm IST

More quotes
ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
Calendar
More about the company